Valbenazine

(Ingrezza)

Valbenazine

Drug updated on 11/13/2023

Dosage FormCapsule (oral: 40 mg, 60 mg, 80 mg)
Drug ClassVesicular monoamine transporter 2 inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults with tardive dyskinesia.
  • For the treatment of chorea associated with Huntington’s disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Ingrezza (valbenazine) Prescribing Information.2023Neurocrine Biosciences, Inc., San Diego, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines